Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18094465 | 0.86 | MPL (0.49) | ADORA3RXFP1MAPTTRPV1 | |
| SCHEMBL18094520 | 0.86 | MPL (0.45) | ADORA3RXFP1MAPTTRPV1 | |
| SCHEMBL16718882 | 0.85 | MPL (0.51) | ADORA3MAPT | |
| SCHEMBL18094497 | 0.83 | LSS (0.46) | ADORA3HDAC1RXFP1MAPTHIF1A | |
| SCHEMBL18094467 | 0.81 | BRAF (0.47) | MAPT | |
| SCHEMBL18094539 | 0.80 | ADORA3 (0.58) | ADORA3RXFP1MAPTMAPK14TRPV1 | |
| SCHEMBL18094462 | 0.80 | HTR2A (0.44) | KCNH2MAPTHIF1AEPAS1 | |
| SCHEMBL18094532 | 0.79 | TRPV1 (0.45) | ADORA3HDAC1RXFP1MAPTTRPV1 | |
| SCHEMBL18094557 | 0.79 | MAPT (0.53) | ADORA3RXFP1MAPTTRPV1 | |
| SCHEMBL18094482 | 0.78 | TRPV1 (0.60) | ADORA3RXFP1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170202849-A1 | ANTIPARASITIC COMPOUNDS | AVISTA PHARMA SOLUTIONS, INC. | 2017-07-20 | — | — | US | claimed |
| US-9643963-B2 | Antiparasitic compounds | AVISTA PHARMA SOLUTIONS, INC. (US) | 2017-05-09 | — | — | US | claimed |
| US-20160280700-A1 | ANTIPARASITIC COMPOUNDS | SNAPDRAGON CHEMISTRY, INC. | 2016-09-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280700-A1 | ANTIPARASITIC COMPOUNDS | TPP2, TPP1, SERPINB1 | ADORA3 648/4885KCNH2 1666/4885HDAC1 906/4885 |
| US-20170202849-A1 | ANTIPARASITIC COMPOUNDS | TPP2, TPP1, SERPINB1 | ADORA3 648/4885KCNH2 1666/4885HDAC1 906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.